Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease (vol 79, pg 555, 2019)

被引：1
|
作者：
Shirley, Matt [1 ]
机构：
[1] Springer, Private Bag 65901, Auckland 0754, New Zealand
来源：
DRUGS | 2019年 / 79卷 / 07期
关键词：
D O I：
10.1007/s40265-019-01111-2
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The article Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease.
引用
收藏
页码：791 / 791
页数：1
相关论文
共 50 条
  • [21] A Retrospective Analysis to Assess the Discontinuation of Amikacin Liposome Inhalation Suspension Therapy Among Patients Treated for Refractory Mycobacterium Avium Complex Lung Disease
    Puc, M.
    Koerner, P.
    Russian, A.
    Faris, R.
    Vanscoy, G.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [22] Amikacin Liposome Inhalation Suspension (ALIS) for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease: Effect of Baseline Amikacin and Clarithromycin Susceptibility on Culture Conversion
    Winthrop, K. L.
    Flume, P. A.
    Thomson, R.
    Brown-Elliott, B. A.
    Wallace, R. J., Jr.
    Griffith, D. E.
    Pennings, L. J.
    Coulter, C.
    Syrmis, M.
    Pandey, S.
    Yuen, D.
    Mange, K.
    van Ingen, J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [23] A Case of Single-lung Transplant in a Patient with Mycobacterium avium Pulmonary Disease Successfully Treated with Amikacin Liposome Inhalation Suspension
    Ozeki, Taichi
    Higo, Hisao
    Omori, Hiroki
    Mori, Shunta
    Tanaka, Shin
    Makimoto, Go
    Ninomiya, Kiichiro
    Taniguchi, Akihiko
    Fujii, Masanori
    Miyoshi, Kentaro
    Rai, Kammei
    Ichihara, Eiki
    Ohashi, Kadoaki
    Sugimoto, Seiichiro
    Hotta, Katsuyuki
    Tabata, Masahiro
    Toyooka, Shinichi
    Maeda, Yoshinobu
    Miyahara, Nobuaki
    INTERNAL MEDICINE, 2024,
  • [24] Amikacin Liposome Inhalation Suspension for Refractory Mycobacterium avium Complex Lung Disease Sustainability and Durability of Culture Conversion and Safety of Long-term Exposure
    Griffith, David E.
    Thomson, Rachel
    Flume, Patrick A.
    Aksamit, Timothy R.
    Field, Stephen K.
    Addrizzo-Harris, Doreen J.
    Morimoto, Kozo
    Hoefsloot, Wouter
    Mange, Kevin C.
    Yuen, Dayton W.
    Ciesielska, Monika
    Wallace, Richard J., Jr.
    van Ingen, Jakko
    Brown-Elliott, Barbara A.
    Coulter, Chris
    Winthrop, Kevin L.
    CHEST, 2021, 160 (03) : 831 - 842
  • [25] Open-Label Trial of Amikacin Liposome Inhalation Suspension in Mycobacterium abscessus Lung Disease
    Siegel, Sarah A. R.
    Griffith, David E.
    Philley, Julie V.
    Brown-Elliott, Barbara A.
    Brunton, Amanda E.
    Sullivan, Peter E.
    Fuss, Cristina
    Strnad, Luke
    Wallace Jr, Richard J.
    Winthrop, Kevin L.
    CHEST, 2023, 164 (04) : 846 - 859
  • [26] Diagnosis and Management of Drug-Induced Interstitial Lung Disease Associated with Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium Avium Complex Pulmonary Disease: A Case Report
    Hashimoto, Kazuki
    Nii, Takuro
    Sumitani, Hitoshi
    Yokoyama, Masashi
    Miyamoto, Satoshi
    Mihashi, Yasuhiro
    Nagata, Yuka
    Matsuki, Takanori
    Tsujino, Kazuyuki
    Miki, Keisuke
    Kida, Hiroshi
    INFECTION AND DRUG RESISTANCE, 2023, 16 : 6629 - 6634
  • [27] AN OPEN-LABEL EXTENSION STUDY OF AMIKACIN LIPOSOME INHALATION SUSPENSION (ALIS) FOR TREATMENT-REFRACTORY LUNG DISEASE CAUSED BY MYCOBACTERIUM AVIUM COMPLEX (MAC)
    Winthrop, Kevin
    Morimoto, Kozo
    Castellotti, Paola Francesca
    Yim, Jae-Joon
    Ruoss, Stephen
    van Ingen, Jakko
    Coulter, Christopher
    Mange, Kevin
    Nezamis, James
    Griffith, David
    CHEST, 2019, 156 (04) : 146A - 147A
  • [28] Amikacin liposome inhalation suspension for Mycobacterium avium complex pulmonary disease: A subgroup analysis of Japanese patients in the randomized, phase 3, CONVERT study
    Morimoto, Kozo
    Nonaka, Mizu
    Yamazaki, Yoshitaka
    Nakagawa, Taku
    Takasaki, Jin
    Tsuyuguchi, Kazunari
    Kitada, Seigo
    Jumadilova, Zhanna
    Yuen, Dayton W.
    Ciesielska, Monika
    Hasegawa, Naoki
    RESPIRATORY INVESTIGATION, 2024, 62 (02) : 284 - 290
  • [29] ALIS (Amikacin Liposome Inhalation Suspension) for the Treatment of Patients with Refractory Mycobacterium avium Complex Lung Disease (MACLD) the Number Needed to Treat (NNT) and Number Needed to Harm (NNH)
    Marras, T. K.
    Hassan, M.
    Mange, K. C.
    Ciesielska, M.
    Sonnenahalli, S. Dhar
    Jumadilova, Z.
    Chatterjee, A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [30] RELATIONSHIP BETWEEN IN VITRO CLARITHROMYCIN SUSCEPTIBILITY AND SPUTUM CULTURE CONVERSION WITH ADD-ON AMIKACIN LIPOSOME INHALATION SUSPENSION (ALIS) FOR TREATMENT OF REFRACTORY MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE
    Griffith, David
    Eagle, Gina
    Wallace, Richard
    Brown-Elliott, Barbara
    Van Ingen, Jakko
    Pennings, Lian
    Berry, Brooke
    Pandey, Sushil
    Coulter, Christopher
    Syrmis, Melanie
    Morimoto, Kozo
    Hasegawa, Naoki
    CHEST, 2018, 154 (04) : 109A - 110A
12345